Clinical Cases in Pharmacology Clinical Cases  ·  Psychiatry II  ·  Trauma- and Stressor-Related Disorders  ·  PTSD Medication Choice With Comorbid TBI
Psychiatry II, Trauma-0013 — Trauma- and Stressor-Related Disorders

PTSD Medication Choice in Combat Veterans With Comorbid Traumatic Brain Injury

Blast-related traumatic brain injury and PTSD are frequently comorbid in combat veterans, and a TBI-lowered seizure threshold quietly rules out one antidepressant class entirely before the pharmacologic conversation even reaches which drug helps most.

Abbreviations, terms, and other agents mentioned in this case PTSD — posttraumatic stress disorder  ·  TBI — traumatic brain injury  ·  SSRI — selective serotonin reuptake inhibitor  ·  NDRI — norepinephrine-dopamine reuptake inhibitor
Presentation

J.T. is a 30-year-old man, an Army veteran now working as an apprentice electrician, who sustained two documented blast exposures during his second deployment, the more significant of which left him briefly unconscious and earned a formal diagnosis of mild traumatic brain injury on his discharge paperwork. He lives with his fiancee and her young daughter, and describes his PTSD symptoms — nightmares, irritability, and a persistent difficulty concentrating that he initially attributed entirely to the TBI — as having worsened gradually over the two years since he separated from the service.

His TBI history is not incidental background here; it directly narrows the medication conversation before efficacy is even discussed. Bupropion, an agent some clinicians reach for when depressive and concentration symptoms are prominent, lowers seizure threshold in a dose-dependent way, and the labeling is explicit about it: bupropion is contraindicated in patients with a seizure disorder, and the extended-release labeling extends that contraindication to conditions that raise seizure risk, naming severe head injury among them. J.T.'s injury is documented as mild TBI, so the label's exclusion does not automatically capture him — the honest reading is that he sits in the space between a formal contraindication and an ordinary precaution, with a blast mechanism and a documented loss of consciousness on the cautious side of it. Tricyclic antidepressants also lower seizure threshold and add anticholinergic cognitive burden on top of an already TBI-affected brain, making them a poor fit twice over. What remains is not a narrowed field because nothing else works — SSRIs carry no comparable seizure-threshold concern and are, if anything, the more conservative, better-tolerated choice for a TBI-affected patient specifically, which makes this less a compromise than it might first appear.

J.T. · 30 New consult
History
PTSD, 2 years; blast-related mild TBI with brief loss of consciousness, documented at discharge
Symptoms
Nightmares, irritability, concentration difficulty
Seizure history
None reported, but TBI-related seizure-threshold reduction is a documented risk factor
Function
Employed as apprentice electrician, stable home life
Prior treatment
None

At the intake visit

Clinical Pharmacologist Opening

I'd take bupropion off the table here, though I want to be accurate about why. His TBI is documented as mild, so this isn't the label's severe head injury contraindication firing automatically — it's a blast mechanism with a documented loss of consciousness in a patient who has an equally good alternative and no particular reason to need this drug. When the seizure-threshold question is genuinely borderline and nothing is lost by avoiding it, avoid it. Tricyclics lower the threshold too and add meaningful anticholinergic cognitive burden, which is its own separate reason to avoid them in a TBI-affected brain.

Attending Psychiatrist Response

Agreed on both exclusions. I want to be clear with him that this isn't a case of settling for a second-choice drug because his best options are unsafe — SSRIs have solid evidence in PTSD on their own merits and carry no comparable seizure or cognitive burden, so this is closer to the conservative, well-supported choice landing in the same place as the safety constraint.

Primary Care Physician Final

One thing worth doing before starting anything: confirm his concentration difficulty is being properly attributed between the TBI and the PTSD, since he mentioned assuming it was "just the TBI" and may not realize an SSRI could meaningfully help the piece that's actually driven by the PTSD rather than the injury itself.

Regimen selected
Sertraline
SSRI · Started, 25 mg titrating
No meaningful seizure-threshold effect and no added anticholinergic cognitive burden, making it well-suited specifically for a TBI-affected patient.
Bupropion
NDRI · Avoided
Dose-dependently lowers seizure threshold; his TBI is documented as mild rather than severe, so this is cautious avoidance in a borderline case with an equally good alternative, not an automatic label contraindication.
Amitriptyline (Tricyclic)
Ruled out
Real seizure-threshold liability plus anticholinergic cognitive burden, a poor fit for a TBI-affected brain on two separate grounds.
Where this was left

Sertraline started at 25 mg with a plan to titrate, alongside a discussion clarifying which of his symptoms are more likely PTSD-driven versus TBI-driven.

Agreed clearly and without residual tension: the TBI history did not leave J.T. with a compromised second-choice option. It steered the team away from two specific agents — bupropion on a cautious reading of a borderline seizure-threshold question rather than an automatic label exclusion, tricyclics on both seizure and anticholinergic grounds — while leaving the actual best-evidenced PTSD treatment fully available to him.

Educational content only — a composite teaching case, not a real patient encounter or a substitute for clinical guidance. About These Cases →